Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

184.74 +1.77 (+0.96%)
Streaming Delayed Price Updated: 2:50 PM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 371,579
Open 183.99
Bid (Size) 184.62 (200)
Ask (Size) 184.85 (100)
Prev. Close 182.97
Today's Range 180.75 - 185.86
52wk Range 96.09 - 191.50
Shares Outstanding 47,190,970
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Is This Healthcare Stock a Millionaire Maker? ↗
If it can establish itself as a leading biotech in the future, it might be. 
Via The Motley Fool
Topics Initial Public Offering Intellectual Property
News headline image
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+3.4%
+3.4%
1 Month
+17.8%
+17.8%
3 Month
+0.1%
+0.1%
6 Month
+40.6%
+40.6%
1 Year
+79.4%
+79.4%

More News

Read More
News headline image
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
Via The Motley Fool
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q4 2025 Results, Meeting Revenue Forecasts but Posting Wider Loss ↗
Via Chartmill
AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy ↗
Via Chartmill
News headline image
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗
Via The Motley Fool
News headline image
2 Under-the-Radar Stocks to Buy and Hold ↗
Via The Motley Fool
News headline image
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs
Via MarketMinute
Topics Economy Initial Public Offering
News headline image
Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Axsome (AXSM) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Should You Buy Axsome Therapeutics Stock Before Feb. 23? ↗
Via The Motley Fool
News headline image
1 High-Flying Stock With More Upside Ahead ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
From Axsome Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
What is the current price of Axsome Therapeutics, Inc. - Common Stock?
The current price of Axsome Therapeutics, Inc. - Common Stock is 184.74
When was Axsome Therapeutics, Inc. - Common Stock last traded?
The last trade of Axsome Therapeutics, Inc. - Common Stock was at 04/22/26 02:50 PM ET
What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 8.72B
How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
Axsome Therapeutics, Inc. - Common Stock has 9B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.